Pomdoctor FY25 net loss widens to RMB 130.9 million; revenue rises 16.7% to RMB 399.9 million

• Pomdoctor posted fiscal 2025 net revenues of RMB 399.9 million, up 16.7%, while net loss widened to RMB 130.9 million.
• Gross profit rose 9.6% to RMB 52.3 million, though gross margin slipped 0.8 percentage point to 13.1%.
• Internet hospital net revenues climbed 69.3% to RMB 150.7 million, while pharmaceutical supply chain net revenues fell 1.7% to RMB 249.2 million.
• Operating expenses jumped to RMB 170.9 million from RMB 73.5 million, as R&D spending more than quadrupled to RMB 12.9 million.
• CEO Zhenyang Shi said 2025 growth was driven by Internet hospital momentum, while the loss reflected non-recurring IPO-related costs; strategy centers on “AI + medical-grade smart wearables + full-cycle chronic disease management” and deeper pharma and insurance-system integration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pomdoctor Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-056781), on May 14, 2026, and is solely responsible for the information contained therein.